{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:10Z","timestamp":1792791070288,"version":"4.5.0"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Neurosurg"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aims to assess the efficacy and safety of antiplatelets (oral and subcutaneous) and anticoagulants for secondary stroke prevention in ischemic stroke patients with cancer, where the optimal antithrombotic strategy remains unclear. A systematic review and meta-analysis were conducted using PubMed, Cochrane Library, and Scopus (inception to June 2024). Studies were screened based on predefined criteria and assessed with the Newcastle-Ottawa Scale. A random-effects model (R 4.1.2) was used to calculate odds ratios (OR) with 95% confidence intervals (CI). A total of four studies were included in the final analysis. The cumulative sample size was 2,781 participants: 2,204 (79.2%) were treated with antiplatelets and 577 (20.7%) were treated with anti-coagulants. The mean age (\u00b1\u2009SD) of the patients was 69.56 (\u00b19.88) years, and 65.7% were men. There was no difference in the risk of recurrent ischemic stroke between antiplatelets and anticoagulants (OR\u2009=\u20090.74, 95% CI: 0.31\u20131.77, 3 studies with 700 patients). There were no differences in the risk of gastrointestinal hemorrhage (OR\u2009=\u20091.74, 95% CI: 0.17\u201317.46, 2 studies with 2,101 patients) and any major hemorrhage (OR\u2009=\u20090.70, 95% CI: 0.24\u20132.05, 4 studies with 2781 patients). The odds of all-cause mortality were lower in patients treated with antiplatelets (OR\u2009=\u20090.73, 95% CI: 0.59\u20130.90, 4 studies involving 2,781 patients). Antiplatelets and anticoagulants showed no difference in recurrent stroke or major hemorrhagic events, but antiplatelets were associated with lower mortality. However, due to limited data, these findings may not fully answer the clinical question, highlighting the need for further high-quality studies.<\/jats:p>","DOI":"10.1055\/s-0045-1813646","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:23:21Z","timestamp":1764807801000},"page":"038-045","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Antiplatelets and Anticoagulants for Secondary Stroke Prevention in Ischemic Stroke Patients with Cancer: A Meta-Analysis"],"prefix":"10.1055","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-1584","authenticated-orcid":false,"given":"Muhammad","family":"Shakir","sequence":"additional","affiliation":[{"name":"Zeenat Qureshi Stroke Institute, and Department of Neurology, University of Missouri, Columbia, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeez","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Zeenat Qureshi Stroke Institute, and Department of Neurology, University of Missouri, Columbia, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9587-7902","authenticated-orcid":false,"given":"Hammad A.","family":"Irshad","sequence":"additional","affiliation":[{"name":"Medical College, Aga Khan University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafay","family":"Salman","sequence":"additional","affiliation":[{"name":"Medical College, Aga Khan University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0238-2057","authenticated-orcid":false,"given":"Eisha A.","family":"Ali","sequence":"additional","affiliation":[{"name":"Medical College, University College of Medicine and Dentistry, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Johns Hopkins University, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Mehr","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, University of Missouri, Columbia, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun S.","family":"Kwok","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mid Cheshire Hospitals NHS Trust, Crewe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Ziai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan I.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Zeenat Qureshi Stroke Institute, and Department of Neurology, University of Missouri, Columbia, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2019.02278","article-title":"Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms","volume":"22","author":"O Y Bang","year":"2020","journal-title":"J Stroke"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.11.016","article-title":"Trends in cancer diagnoses among inpatients hospitalized with stroke","volume":"22","author":"N Sanossian","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"B B Navi","year":"2014","journal-title":"Neurology"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial","volume":"75","author":"B B Navi","year":"2018","journal-title":"JAMA Neurol"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"D O Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S 02","key":"ref7","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"M Mandal\u00e0","year":"2010","journal-title":"Thromb Res"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"M B Streiff","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"D Farge","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref10","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"M Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"J AC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12883-023-03208-4","article-title":"Bleeding risk and mortality according to antithrombotic agents' exposure in cancer-related stroke patients: nationwide population-based cohort study in South Korea","volume":"23","author":"B K Choi","year":"2023","journal-title":"BMC Neurol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial","volume":"27","author":"N Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"R G Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/jamaneurol.2024.2404","article-title":"Apixaban vs aspirin in patients with cancer and cryptogenic stroke: a post hoc analysis of the ARCADIA randomized clinical trial","volume":"81","author":"B B Navi","year":"2024","journal-title":"JAMA Neurol"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial","volume":"331","author":"H Kamel","year":"2024","journal-title":"JAMA"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5853\/jos.2016.00570","article-title":"Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study","volume":"19","author":"M J Lee","year":"2017","journal-title":"J Stroke"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1212\/WNL.0000000000205983","article-title":"Secondary prevention for ischemic stroke in patients with cancer: a systematic review and network meta-analysis (P3-5.024)","volume":"102","author":"L Pipek","year":"2024","journal-title":"Neurology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"B I Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.08.016","article-title":"Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism","volume":"206","author":"G Yamaura","year":"2021","journal-title":"Thromb Res"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.029","article-title":"Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant","volume":"26","author":"K W Nam","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3332\/ecancer.2021.1258","article-title":"Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers","volume":"15","author":"P C Elwood","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00228-022-03414-y","article-title":"Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis","volume":"79","author":"S Ma","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00432-022-03942-1","article-title":"Meta-analysis of aspirin-guided therapy of colorectal cancer","volume":"148","author":"J C M\u00e4dge","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1182\/blood-2017-02-769893","article-title":"Role of ADP receptors on platelets in the growth of ovarian cancer","volume":"130","author":"M S Cho","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ijc.28997","article-title":"Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo","volume":"136","author":"S Mezouar","year":"2015","journal-title":"Int J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fneur.2019.00233","article-title":"Radiotherapy exposure in cancer patients and subsequent risk of stroke: a systematic review and meta-analysis","volume":"10","author":"R Huang","year":"2019","journal-title":"Front Neurol"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/STROKEAHA.118.021373","article-title":"Risk of ischemic and hemorrhagic strokes in occult and manifest cancers","volume":"49","author":"K K Andersen","year":"2018","journal-title":"Stroke"}],"container-title":["Asian Journal of Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1813646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:32:00Z","timestamp":1772602320000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1813646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":28,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1813646","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1793-5482","2248-9614"],"issn-type":[{"value":"1793-5482","type":"print"},{"value":"2248-9614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}